Open Accessibility Menu

Stephen H. Yandel

About Stephen

Dr. Stephen Yandel completed his medical degree from Nova Southeastern University and received the prestigious President and Dean awards. Dr. Yandel finished his internship and residency in Internal Medicine at Sun Coast Hospital in Largo. He continued on to specialize in hematology and oncology and completed his residency at the H. Lee Moffitt Cancer Center in Tampa.

In his 25-year career, Dr. Yandel served as Chief of Medical Staff, Chairman-Department of Internal Medicine and Oncology Rehabilitation Director at hospitals throughout Brevard County. Dr. Yandel was instrumental in creating national protocols for cancer-related treatments and diagnostic imaging.

Dr. Yandel is board-certified in Hematology and Oncology and is an active member of the Florida Osteopathic Medical Association.


  • The Johns Hopkins University, Baltimore, MD, Bachelor of Arts Degree: Biology 1982
  • Southeastern University of the Health Sciences, N. Miami Beach, FL, College of Osteopathic Medicine, Doctor of Osteopathic Medicine 1989
  • Medical School
  • Doctor of Osteopathic Medicine Nova Southeastern University of Health Sciences
    Davie, FL
  • College
  • BA - Biology The Johns Hopkins University
    Baltimore, MD
  • Internship
  • Internal Medicine Sun Coast Hospital
    Largo, FL
  • Residency
  • Internal Medicine Residency Sun Coast Hospital
    Largo, FL
  • Training
  • Subspecialty Resident - Medical Oncology and Hematology H. Lee Moffitt Cancer Center
    Tampa, FL
Medical Interests Research Interests:

Clinical Research:

  • A randomized1 Phase 3 study of Sunitinlb in combination with Capecitabine compared with Capecitablne in patients with previously treated breast cancer
  • A Phase 3 study ofSU011248 in combination with Paclitaxel versus Bevacizumab with Paditaxel in the first line advanced disease setting in patients having breast cancer
  • A randomized, Phase IIIB/IV1 multicenter trial comparing two dosing regiments of xxx(weekly x 4 + 2-week rest versus every - 3 - weeks) in patients with metastatic colorectal after treatment -failure with yyy
  • Survival in an International phase HI prospective randomized LD small cell lung cancer vaccination study with adjuvant xxx and xxx
  • A Phase IV, single - arm, open label study of xxx in prostate cancer patients
  • A Phase [II, randomized, open - label, multicenter, international study comparing combination of www/xxx/yyy/zzz alone in first line therapy of patients with previously untreated metastatic colorectal cancer
  • Clinical outcomes in patients with HER2 gene-amplified metastatic breast cancer treated with first line xxx in combination with yyy: A Phase IV, prospective community based study
  • A randomized, open label, comparative study to estimate the effect of XXX on hospital days, economic outcomes, and health related quality of life in subjects with nonmyeloid malignancies and anemia of cancer
  • A Phase II, randomized trial of XXX plus YYY vs. ZZZ plus XXX in patients with metastatic breast cancer
  • A Multi-center, randomized clinical investigation of XXX versus continued therapy in patients receiving YYY or m for advanced prostate cancer
  • Multi-center, randomized, double-blind, placebo-controlled study of the safety and efficacy of XXX fin the treatment of fatigue and neurobehavioral impairment related to chemotherapy in adult cancer subjects
  • A randomized, multicenter study of combination therapy followed by subsequent single agent XXX maintenance therapy or best supportive care in advanced non-small cell Jung cancer (NSCLC)
  • A phase II, multicenter, randomized, double-bllnd study to evaluate the safety and efficacy of xxx for restoring function on occluded central venous catheters
  • A twelve-week, double-blind, randomized, placebo-controlled, parallel group phase II study of the safety and efficacy of XXX in patients with cancer anorexia/.cachexia with a four-week open-label extension
  • A phase Ill study of XXX ln combination with Paclitaxel versus Bevacizumab with Paclitaxel in the first-line advanced disease setting in patients having breast cancer
  • A randomized, phase 3 study of XXX in combination with Capecitabine in patients with previously treated breast cancer